(IN BRIEF) AstraZeneca's supplemental New Drug Application (sNDA) for Tagrisso (osimertinib) in combination with chemotherapy has been granted Priority Review…
(IN BRIEF) AstraZeneca has unveiled data from four pivotal Phase III trials at the European Society for Medical Oncology (ESMO)…
(IN BRIEF) AstraZeneca is advancing its lung cancer portfolio at the International Association for the Study of Lung Cancer (IASLC)…